Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules
Evaluation of DNA Methylation Signatures in Diagnosis and Management of Thyroid Nodules
City of Hope Medical Center
1,450 participants
Oct 22, 2021
INTERVENTIONAL
Conditions
Summary
This clinical trial evaluates deoxyribonucleic acid (DNA) methylation signatures in diagnosing and managing thyroid nodules. The purpose of this research is to develop a new test for thyroid cancer. This test will use needle biopsies (small collections of tissue with a needle) from the thyroid to determine whether the participant has a malignant (cancer) or benign (not showing cancer) thyroid tumor. The information learned from this trial may help develop a more accurate test so that patients do not have unnecessary surgeries for nodules that are thought to be suspicious but are actually benign.
Eligibility
Inclusion Criteria4
- Patients without impaired decision-making capacity and who are undergoing needle biopsies for thyroid nodule diagnosis
- Over the age of 18
- Any gender, race and ethnicity
- Patients must provide informed consent prior to use of their tissues and clinical data
Exclusion Criteria1
- Children are excluded from the study, since the biology of children thyroid nodules is different from adults
Interventions
Analysis via DDMS-2
Review of medical records
Undergo needle biopsy
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05229341